Press Releases - Onyx Newsroom (Page 15)

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2 analyses for pilavapadin (LX9211) at the 19th Annual Pain Therapeutics Summit, confirming the 10 mg once-daily dose as the optimal candidate for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). The findings—demonstrating validated biological activity, clinically meaningful pain reduction,

October 14, 2025

Affinia Therapeutics to Participate in Upcoming Investor Conferences

✨ Onyx Summary Affinia Therapeutics CEO Rick Modi will participate in a panel on in vivo gene therapies for genetic cardiac diseases at Chardan’s 9th Annual Genetic Medicines Conference on Oct. 21 and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference in London on Nov. 17–

October 14, 2025

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

✨ Onyx Summary Rocket Pharmaceuticals announced that the U.S. FDA has accepted its resubmitted BLA for KRESLADI™ (marnetegragene autotemcel; marne-cel), an investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), setting a PDUFA date of March 28, 2026. The filing is supported by Phase 1/2 data

October 14, 2025

Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation

✨ Onyx Summary Verily has entered a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to advance precision medicine through AI-driven data integration and analytics on Verily’s healthcare technology platform. The partnership will create AI-ready biomedical data pipelines, develop novel models across major

October 14, 2025

Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control

✨ Onyx Summary Excellergy, a Palo Alto–based biotechnology company, launched with a $70 million Series A financing led by Samsara BioCapital to advance its first-in-class Effector Cell Response Inhibitors (ECRIs), a novel therapeutic platform targeting IgE-mediated allergic disease. The funding will support the company’s move into

October 13, 2025

Geron Corporation Announces Executive Leadership Transitions and Appointments

✨ Onyx Summary Geron Corporation announced multiple leadership changes to align with its commercial growth strategy, including the appointment of Ahmed ElNawawi as EVP and Chief Commercial Officer, alongside new senior hires in technical operations, investor relations, and portfolio management. These appointments strengthen Geron’s leadership capabilities as it drives commercialization

October 13, 2025

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

✨ Onyx Summary Avidity Biosciences completed a positive pre-BLA meeting with the U.S. FDA for delpacibart zotadirsen (del-zota), its investigational Duchenne muscular dystrophy (DMD44) therapy, and now plans to file the BLA in Q1 2026 to include additional CMC data. The company’s first planned BLA submission marks

October 13, 2025

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

✨ Onyx Summary Seer, Inc. announced its participation at the 2025 American Society of Human Genetics Annual Meeting, where it will showcase how its Proteograph® Product Suite enables integration of proteomics and genomics to advance precision medicine. The company will host a featured CoLab session and support multiple scientific presentations demonstrating

October 10, 2025

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

✨ Onyx Summary Rocket Pharmaceuticals granted inducement equity awards to newly appointed Chief Medical Officer Dr. Syed Rizvi, consisting of stock options and restricted stock units totaling approximately 729,765 shares. The awards, approved under Nasdaq’s inducement grant rule, align long-term incentives with Rocket’s strategic growth as it

October 10, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

✨ Onyx Summary Lexicon Pharmaceuticals hosted a policy roundtable in Washington, DC, bringing together clinicians, patient advocates, and industry experts to discuss expanding the scope of the federal “Alternatives to PAIN Act” to include chronic pain sufferers, beyond its current focus on acute and post-surgical pain. CEO Mike Exton emphasized

October 8, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

✨ Onyx Summary Lexicon Pharmaceuticals convened a policy roundtable in Washington, D.C., with clinicians, advocates, and patients to discuss expanding the Alternatives to PAIN Act to include chronic pain patients under Medicare Part D coverage for non-opioid treatments. The company plans to publish a White Paper summarizing insights from

October 8, 2025

Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy

✨ Onyx Summary Affinia Therapeutics closed a $40 million Series C financing led by NEA with participation from Eli Lilly and existing investors to advance its lead gene therapy candidate AFTX-201 for BAG3 dilated cardiomyopathy (DCM). The proceeds will support IND submission in Q4 2025 and initiation of the Phase

October 7, 2025

Aspect Biosystems to Present at 2025 Cell & Gene Meeting on the Mesa

✨ Onyx Summary Aspect Biosystems Chief Scientific Officer Sam Wadsworth will present at the 2025 Cell & Gene Meeting on the Mesa on October 7 in Phoenix, highlighting the company’s advancements in regenerative medicine. The annual conference, organized by the Alliance for Regenerative Medicine, gathers global leaders in cell and

October 6, 2025

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

✨ Onyx Summary Avidity Biosciences will present new one-year data on delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD44) at the 30th Annual World Muscle Society Congress, showing reversal of disease progression and improvements across functional measures from its EXPLORE44® and EXPLORE44-OLE™ trials. The presentations, featuring leading clinicians,

October 6, 2025

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

✨ Onyx Summary Phathom Pharmaceuticals appointed Sanjeev Narula as Chief Financial and Business Officer, bringing over two decades of financial leadership experience from Intra-Cellular Therapies, Viatris, and Pfizer. His appointment strengthens Phathom’s executive team as the company advances commercialization of its GI franchise, VOQUEZNA, and pursues its strategy toward

October 6, 2025

MassBio 2025 Patient Advocacy Summit: Purpose, In Spite of Pressure

✨ Onyx Summary MassBio will host the 2025 Patient Advocacy Summit on November 6 at the MassBioHub, themed “Purpose, In Spite of Pressure,” highlighting how patients and advocates drive progress across the healthcare and drug development landscape. The event will feature a keynote by Yelak Biru and Fatima Scipione on the

October 3, 2025